XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

XenTech presents 7 posters at AACR 2018

    Abstract Number: 919 Endogenous STING inhibition induces breast cancer cell death Date and Time: Sunday Apr 15, 2018; 1:00 PM – 5:00 PM Location: Poster Section 41 Poster Board Number: 26 A current cancer immunotherapy strategy proposes the use of STING agonists to boost the patient’s immune system through the cytokine-mediated enhancement of tumor infiltration and […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...